MX347961B - Formulaciones de liberación inmediata resistentes a alteración. - Google Patents

Formulaciones de liberación inmediata resistentes a alteración.

Info

Publication number
MX347961B
MX347961B MX2014003192A MX2014003192A MX347961B MX 347961 B MX347961 B MX 347961B MX 2014003192 A MX2014003192 A MX 2014003192A MX 2014003192 A MX2014003192 A MX 2014003192A MX 347961 B MX347961 B MX 347961B
Authority
MX
Mexico
Prior art keywords
core
dosage form
immediate release
release formulations
tamper resistant
Prior art date
Application number
MX2014003192A
Other languages
English (en)
Spanish (es)
Other versions
MX2014003192A (es
Inventor
Reilly Kevin
Original Assignee
Purdue Pharma Lp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Pharma Lp filed Critical Purdue Pharma Lp
Publication of MX2014003192A publication Critical patent/MX2014003192A/es
Publication of MX347961B publication Critical patent/MX347961B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2014003192A 2011-09-16 2012-09-14 Formulaciones de liberación inmediata resistentes a alteración. MX347961B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161535758P 2011-09-16 2011-09-16
PCT/IB2012/001916 WO2013038268A1 (en) 2011-09-16 2012-09-14 Tamper resistant immediate release formulations

Publications (2)

Publication Number Publication Date
MX2014003192A MX2014003192A (es) 2015-04-13
MX347961B true MX347961B (es) 2017-05-19

Family

ID=48577967

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014003192A MX347961B (es) 2011-09-16 2012-09-14 Formulaciones de liberación inmediata resistentes a alteración.

Country Status (8)

Country Link
US (1) US20140294947A1 (enExample)
EP (2) EP3078370B1 (enExample)
JP (1) JP6138798B2 (enExample)
AU (1) AU2012310251B2 (enExample)
ES (2) ES2583132T3 (enExample)
IL (1) IL231482A (enExample)
MX (1) MX347961B (enExample)
WO (1) WO2013038268A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003024429A1 (en) 2001-09-21 2003-03-27 Egalet A/S Polymer release system
US20040253310A1 (en) 2001-09-21 2004-12-16 Gina Fischer Morphine polymer release system
US8877241B2 (en) 2003-03-26 2014-11-04 Egalet Ltd. Morphine controlled release system
US8821928B2 (en) 2007-06-04 2014-09-02 Egalet Ltd. Controlled release pharmaceutical compositions for prolonged effect
NZ594207A (en) 2009-02-06 2013-03-28 Egalet Ltd Immediate release composition resistant to abuse by intake of alcohol
AU2010265213B2 (en) 2009-06-24 2012-08-23 Egalet Ltd. Controlled release formulations
JP2015521988A (ja) 2012-07-06 2015-08-03 イガレット・リミテッド 制御放出用乱用防止性医薬組成物
CA3042642A1 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
WO2015095391A1 (en) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
DK3169315T3 (da) 2014-07-17 2020-08-10 Pharmaceutical Manufacturing Res Services In Væskefyldt doseringsform til forhindring af misbrug med øjeblikkelig frigivelse
US9132096B1 (en) 2014-09-12 2015-09-15 Alkermes Pharma Ireland Limited Abuse resistant pharmaceutical compositions
AU2015336065A1 (en) 2014-10-20 2017-05-04 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
EP3691645A4 (en) * 2017-10-02 2021-06-23 Purdue Pharma L.P. Pharmaceutical compositions comprising delayed release gelling agent compositions
US12161754B2 (en) 2017-12-20 2024-12-10 Purdue Pharma L.P. Abuse deterrent morphine sulfate dosage forms

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9401894D0 (en) * 1994-02-01 1994-03-30 Rhone Poulenc Rorer Ltd New compositions of matter
US5654005A (en) * 1995-06-07 1997-08-05 Andrx Pharmaceuticals, Inc. Controlled release formulation having a preformed passageway
WO2004026308A1 (en) * 2002-09-21 2004-04-01 Shuyi Zhang Sustained release compound of acetamidophenol and tramadol
BRPI0415557A (pt) * 2003-10-31 2006-12-26 Hexal Ag formulação contendo ingrediente ativo farmacêutico com revestimento
EP1691892B1 (en) * 2003-12-09 2007-02-28 Euro-Celtique S.A. Tamper resistant co-extruded dosage form containing an active agent and an adverse agent and process of making same
TWI365880B (en) 2004-03-30 2012-06-11 Euro Celtique Sa Process for preparing oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone and oxycodone hydrochloride composition,pharmaceutical dosage form,sustained release oeal dosage form and pharmaceutically acceptable package having less than 25 pp
US20080152595A1 (en) * 2004-11-24 2008-06-26 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
US8652529B2 (en) * 2005-11-10 2014-02-18 Flamel Technologies Anti-misuse microparticulate oral pharmaceutical form
US9023400B2 (en) * 2006-05-24 2015-05-05 Flamel Technologies Prolonged-release multimicroparticulate oral pharmaceutical form
SI2484346T1 (sl) * 2006-06-19 2017-05-31 Alpharma Pharmaceuticals Llc Farmacevtski sestavki
SA07280459B1 (ar) * 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
CN105534936B (zh) * 2007-08-13 2020-07-31 Ohemo 生命科学股份有限公司 抗滥用药物、使用方法和制备方法
PL2079446T3 (pl) * 2007-08-21 2012-04-30 Teva Pharma Preparat paliperidonu o przedłużonym uwalnianiu
US20110123575A1 (en) * 2008-06-02 2011-05-26 Dr. Reddy's Laboratories Ltd. Modified release niacin formulations
PH12013501345A1 (en) * 2010-12-23 2022-10-24 Purdue Pharma Lp Tamper resistant solid oral dosage forms
BR112014002022A2 (pt) * 2011-07-29 2017-02-21 Gruenenthal Gmbh comprimido resistente à violação proporcionando liberação de fármaco imediata

Also Published As

Publication number Publication date
MX2014003192A (es) 2015-04-13
WO2013038268A8 (en) 2013-06-13
AU2012310251A8 (en) 2013-06-20
AU2012310251B2 (en) 2016-01-21
ES2703688T3 (es) 2019-03-12
IL231482A (en) 2017-03-30
JP6138798B2 (ja) 2017-05-31
EP2755638A1 (en) 2014-07-23
EP2755638B1 (en) 2016-06-01
JP2014530185A (ja) 2014-11-17
AU2012310251A1 (en) 2013-05-09
IL231482A0 (en) 2014-04-30
EP3078370B1 (en) 2018-11-07
EP3078370A1 (en) 2016-10-12
WO2013038268A1 (en) 2013-03-21
US20140294947A1 (en) 2014-10-02
ES2583132T3 (es) 2016-09-19

Similar Documents

Publication Publication Date Title
MX2014003192A (es) Formulaciones de liberación inmediata resistentes a alteración.
MX355478B (es) Formulaciones farmacéuticas resistentes a la manipulación.
NZ629468A (en) Tamper resistant immediate release formulations
PH12015501756A1 (en) Tamper resistant pharmaceutical formulations
UA115139C2 (uk) Спосіб доставки фармацевтичної композиції, яка містить омепразол й ацетилсаліцилову кислоту, пацієнту
MX2023006414A (es) Paquete de dosificacion unitaria y metodos para administrar medicaciones de perdida de peso.
PH12013500477A1 (en) Aqueous drug delivery system comprising off-flavor masking agent
WO2011107855A3 (en) Sustained release oral liquid suspension dosage form
TN2015000326A1 (en) Tamper resistant pharmaceutical formulations
WO2012091523A3 (en) Carrier for negatively charged drugs comprising a cationic lipid and a preparation method thereof
SG10201901167SA (en) Methods and compositions for treatment of attention deficit disorder
NZ604029A (en) Methods of treating bladder cancer
MX2015006613A (es) Liberacion autorregulada de ingrediente farmaceutico activo.
WO2012052853A3 (en) Oral dosing device for administration of medication
NZ595046A (en) Compositions and methods for extended therapy with aminopyridines
WO2011084316A3 (en) Formulations and methods for controlling mdi particle size delivery
DE602008006700D1 (enExample)
EA201400737A1 (ru) Система доставки на основе множества пеллет с немедленным высвобождением активного вещества
MX394276B (es) Inhalador de polvo seco y metodo de uso
MX2016007181A (es) Medicamentos inhalables.
MX2009003197A (es) Sistema de embalaje para composiciones farmaceuticas y equipo para administracion intravenosa.
EA201591415A1 (ru) Фармацевтические композиции, включающие многокомпонентные кристаллические частицы, подходящие для применения в ингаляционной терапии
EA200971113A1 (ru) Шипучие таблетки для ингаляционного применения
UA80243U (ru) Система доставки лекарств
IN2013MU03390A (enExample)

Legal Events

Date Code Title Description
FG Grant or registration